Kevin Robert Lind - 31 Dec 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Director
Signature
/s/ Christopher Sullivan, by Power of Attorney
Issuer symbol
AVTX
Transactions as of
31 Dec 2025
Net transactions value
+$12,500
Form type
4
Filing time
05 Jan 2026, 16:05:55 UTC
Previous filing
02 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lind Kevin Robert Director C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE /s/ Christopher Sullivan, by Power of Attorney 05 Jan 2026 0001677036

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Award $12,500 +848 $14.74 848 31 Dec 2025 Common Stock 848 $18.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were granted on December 31, 2025, and are 100% vested.